Pacira to Report 2025 Financial Results

Pharmaceutical company Pacira BioSciences to announce Q4 and full-year 2025 financial results on February 26, 2026.

Published on Feb. 12, 2026

Got story updates? Submit your updates here. ›

Pacira BioSciences, Inc., a pharmaceutical company focused on non-opioid pain therapies, announced that it will report its fourth quarter and full-year 2025 financial results after the U.S. market close on Thursday, February 26, 2026. The company will host a live conference call and webcast at 4:30 p.m. ET that day to discuss the results.

Why it matters

As a leader in non-opioid pain management solutions, Pacira's financial performance and product pipeline updates are closely watched by investors and the healthcare industry. The company's ability to continue innovating and growing its portfolio of non-opioid treatments is seen as crucial amid the ongoing opioid crisis.

The details

Pacira has three commercial-stage non-opioid pain treatments: EXPAREL, ZILRETTA, and iovera°. The company is also advancing a pipeline of clinical-stage assets, including PCRX-201, a novel gene therapy for osteoarthritis of the knee that is in Phase 2 development.

  • Pacira will report Q4 and full-year 2025 financial results after the U.S. market close on Thursday, February 26, 2026.
  • The company will host a live conference call and webcast at 4:30 p.m. ET on February 26, 2026 to discuss the results.

The players

Pacira BioSciences, Inc.

A pharmaceutical company that is the industry leader in delivering innovative, non-opioid pain therapies to transform the lives of patients.

Got photos? Submit your photos here. ›

What’s next

Investors and analysts will be closely watching Pacira's financial results and any updates on the company's product pipeline and growth initiatives.

The takeaway

Pacira's focus on developing non-opioid pain management solutions positions the company to play a key role in addressing the ongoing opioid crisis and transforming patient care.